FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213305438> ?p ?o ?g. }

• W4213305438 endingPage "1256" @default.
• W4213305438 startingPage "1243" @default.
• W4213305438 abstract "To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab followed by an antiresorptive resulted in larger increases in bone mineral density of both hip and spine compared with the reverse sequence. Teriparatide followed by an antiresorptive increases bone mineral density (BMD) more than using an antiresorptive first. To evaluate whether treatment sequence affects romosozumab response, we reviewed randomized clinical trials where romosozumab was administered before (ARCH, FRAME) or following (STRUCTURE, Phase 2 extension) an antiresorptive (alendronate or denosumab, respectively). We evaluated BMD percentage change for total hip (TH) and lumbar spine (LS) and response rates (BMD gains ≥ 3% and ≥ 6%) at years 1 and 2 (except STRUCTURE with only 1-year data available). With 1-year romosozumab initial therapy in ARCH and FRAME, TH BMD increased 6.2% and 6.0%, and LS BMD increased 13.7% and 13.1%, respectively. When romosozumab was administered for 1 year after alendronate (STRUCTURE) or denosumab (Phase 2 extension), TH BMD increased 2.9% and 0.9%, respectively, and LS BMD increased 9.8% and 5.3%, respectively. Over 2 years, TH and LS BMD increased 7.1% and 15.2% with romosozumab/alendronate, 8.5% and 16.6% with romosozumab/denosumab, and 3.8% and 11.5% with denosumab/romosozumab, respectively. A greater proportion of patients achieved BMD gains ≥ 6% when romosozumab was used first, particularly for TH, versus the reverse sequence (69% after romosozumab/denosumab; 15% after denosumab/romosozumab). In this study, larger mean BMD increases and greater BMD responder rates were achieved when romosozumab was used before, versus after, an antiresorptive agent. Since BMD on treatment is a strong surrogate for bone strength and fracture risk, this analysis supports the thesis that initial treatment with romosozumab followed by an antiresorptive will result in greater efficacy versus the reverse sequence." @default.
• W4213305438 created "2022-02-24" @default.
• W4213305438 creator A5009972236 @default.
• W4213305438 creator A5011375575 @default.
• W4213305438 creator A5011735451 @default.
• W4213305438 creator A5024994311 @default.
• W4213305438 creator A5028056767 @default.
• W4213305438 creator A5037555787 @default.
• W4213305438 creator A5046515674 @default.
• W4213305438 creator A5047217450 @default.
• W4213305438 creator A5052702193 @default.
• W4213305438 creator A5067638427 @default.
• W4213305438 creator A5069505242 @default.
• W4213305438 creator A5083763741 @default.
• W4213305438 date "2022-02-15" @default.
• W4213305438 modified "2023-10-01" @default.
• W4213305438 title "Romosozumab and antiresorptive treatment: the importance of treatment sequence" @default.
• W4213305438 cites W1906465678 @default.
• W4213305438 cites W1911703092 @default.
• W4213305438 cites W1990771263 @default.
• W4213305438 cites W1992310701 @default.
• W4213305438 cites W1993035292 @default.
• W4213305438 cites W1998642915 @default.
• W4213305438 cites W2023781848 @default.
• W4213305438 cites W2032956576 @default.
• W4213305438 cites W2040386786 @default.
• W4213305438 cites W2042007405 @default.
• W4213305438 cites W2048964656 @default.
• W4213305438 cites W2073076949 @default.
• W4213305438 cites W2073790420 @default.
• W4213305438 cites W2095440374 @default.
• W4213305438 cites W2096627331 @default.
• W4213305438 cites W2108106130 @default.
• W4213305438 cites W2115028313 @default.
• W4213305438 cites W2118914286 @default.
• W4213305438 cites W2127985847 @default.
• W4213305438 cites W2160005424 @default.
• W4213305438 cites W2166468389 @default.
• W4213305438 cites W2335178464 @default.
• W4213305438 cites W2417995089 @default.
• W4213305438 cites W2482825522 @default.
• W4213305438 cites W2516614130 @default.
• W4213305438 cites W2520995084 @default.
• W4213305438 cites W2560207284 @default.
• W4213305438 cites W2583623004 @default.
• W4213305438 cites W2617811370 @default.
• W4213305438 cites W2738136796 @default.
• W4213305438 cites W2754720807 @default.
• W4213305438 cites W2767671304 @default.
• W4213305438 cites W2793982131 @default.
• W4213305438 cites W2799344183 @default.
• W4213305438 cites W2801463953 @default.
• W4213305438 cites W2803459905 @default.
• W4213305438 cites W2903727587 @default.
• W4213305438 cites W2912416377 @default.
• W4213305438 cites W2935325905 @default.
• W4213305438 cites W2955498242 @default.
• W4213305438 cites W2968378996 @default.
• W4213305438 cites W2973632969 @default.
• W4213305438 cites W2980928034 @default.
• W4213305438 cites W3012208209 @default.
• W4213305438 cites W3026845498 @default.
• W4213305438 cites W3030624497 @default.
• W4213305438 cites W3033479596 @default.
• W4213305438 cites W3041733543 @default.
• W4213305438 cites W3048163320 @default.
• W4213305438 cites W3080606503 @default.
• W4213305438 cites W3138944102 @default.
• W4213305438 cites W3155734054 @default.
• W4213305438 cites W3162186590 @default.
• W4213305438 cites W3163284348 @default.
• W4213305438 cites W3174854556 @default.
• W4213305438 cites W3207812367 @default.
• W4213305438 cites W4236641936 @default.
• W4213305438 doi "https://doi.org/10.1007/s00198-021-06174-0" @default.
• W4213305438 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35165774" @default.
• W4213305438 hasPublicationYear "2022" @default.
• W4213305438 type Work @default.
• W4213305438 citedByCount "22" @default.
• W4213305438 countsByYear W42133054382022 @default.
• W4213305438 countsByYear W42133054382023 @default.
• W4213305438 crossrefType "journal-article" @default.
• W4213305438 hasAuthorship W4213305438A5009972236 @default.
• W4213305438 hasAuthorship W4213305438A5011375575 @default.
• W4213305438 hasAuthorship W4213305438A5011735451 @default.
• W4213305438 hasAuthorship W4213305438A5024994311 @default.
• W4213305438 hasAuthorship W4213305438A5028056767 @default.
• W4213305438 hasAuthorship W4213305438A5037555787 @default.
• W4213305438 hasAuthorship W4213305438A5046515674 @default.
• W4213305438 hasAuthorship W4213305438A5047217450 @default.
• W4213305438 hasAuthorship W4213305438A5052702193 @default.
• W4213305438 hasAuthorship W4213305438A5067638427 @default.
• W4213305438 hasAuthorship W4213305438A5069505242 @default.
• W4213305438 hasAuthorship W4213305438A5083763741 @default.
• W4213305438 hasBestOaLocation W42133054381 @default.
• W4213305438 hasConcept C104317684 @default.
• W4213305438 hasConcept C126322002 @default.
• W4213305438 hasConcept C137620995 @default.

• next